London close: Flat finish
30th Jun 2010 15:56
A jumpy start on Wall Street did nothing to steady a volatile Footsie, but despite all the fluctuations the leading index finished hardly changed on the day. London lost 272 points in June, the third monthly decline in a row, and traded a range of well over 400 points. Miners ENRC, Kazakhmys and A
Read moreFTSE 100 movers: Oil companies head higher
30th Jun 2010 15:29
Oil companies are back in favour today as investment banks try to generate fees by suggesting that BP could be taken over. JPMorgan Cazenove suggests Exxon Mobil as a potential suitor. Meanwhile, the FT says Anadarko, a 25% partner to BP on the Macondo prospect in the Gulf of Mexico, approved seve
Read moreTechMARK movers: AstraZeneca protects patents
30th Jun 2010 15:14
Anglo-Swedish drugs developer AstraZeneca has lost some of its early gains but it remains well up on the day after a favourable US court ruling in its battle to keep control of the patents to its best-selling cholesterol-lowering drug Crestor. The ruling means that cheaper, generic versions of Astr
Read moreLondon afternoon: Miners spoil the party
30th Jun 2010 14:15
The Footsie turned south over the lunch time session as traders took note of the US stock futures market which indicates US markets will open mixed and miners took a turn for the worse. Anglo-Swedish drugs giant AstraZeneca is still the best performer after it received a favourable US ruling in it
Read moreUK MARKET TALK ROUNDUP: SHARES GAINING
30th Jun 2010 12:35
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1135 GMT [Dow Jones] Morgan Stanley raises AstraZeneca (AZN.LN) price target to 3690p from 3540p following the company's v
Read moreMARKET TALK: Morgan Stanley Raises AstraZeneca Price Target
30th Jun 2010 12:35
1135 GMT [Dow Jones] Morgan Stanley raises AstraZeneca (AZN.LN) price target to 3690p from 3540p following the company's victory in the Crestor patent case. Says this is worth an extra 150p per share. Adds that while the defendants will no doubt appeal, the historical probability of success is only
Read moreBroker tips: Astra, Smiths Group, HMV
30th Jun 2010 12:23
Panmure Gordon has doffed its hat to AstraZeneca's legal eagles after the drugs giant's favourable verdict in a Delaware court on its CRESTOR patent. "The company's impressive record in intellectual property litigation continues with a win on Crestor to accompany wins on Prilosec, Pulmicort respul
Read moreLondon midday: Respectable gains for Footsie
30th Jun 2010 11:58
Gains in London are now approaching respectable, buoyed by strong demand for heavy hitters in the pharmaceuticals and energy sectors. Anglo-Swedish drugs giant AstraZeneca is the best performer after it received a favourable US ruling in its battle to keep control of the patents to its best-selling
Read moreUK MARKET TALK ROUNDUP: SHARES GAINING
30th Jun 2010 11:55
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1055 GMT [Dow Jones] UBS raises AstraZeneca (AZN.LN) price target to 4100p from 3800p following the company's victory in t
Read moreMARKET TALK: UBS Raises AstraZeneca Price Target
30th Jun 2010 11:55
1055 GMT [Dow Jones] UBS raises AstraZeneca (AZN.LN) price target to 4100p from 3800p following the company's victory in the Crestor patent case. UBS had previously seen 17% of earnings at risk from the US Crestor issue, but the bank notes this risk has now subsided. UBS adds that as Crestor discoun
Read moreBroker snap: Crestor verdict removes Astra overhang
30th Jun 2010 11:43
Panmure Gordon has doffed its hat to AstraZeneca's legal eagles after the drugs giant's favourable verdict in a Delaware court on its CRESTOR patent. "The company's impressive record in intellectual property litigation continues with a win on Crestor to accompany wins on Prilosec , Pulmicort respul
Read moreMARKET TALK: Panmure Raises AstraZeneca Price Target
30th Jun 2010 10:35
0935 GMT [Dow Jones] Panmure Gordon raises AstraZeneca (AZN.LN) price target to 3600p from 3300p, saying the company's Crestor patent victory removes a significant overhang. Expects the company to prevail in any likely appeal which will be conducted by a panel of 3 expert intellectual property lawye
Read moreUK MARKET TALK ROUNDUP: SHARES GAINING
30th Jun 2010 10:35
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0935 GMT [Dow Jones] Panmure Gordon raises AstraZeneca (AZN.LN) price target to 3600p from 3300p, saying the company's Cre
Read moreAstraZeneca Buys Back 0.7M Shares At 2955P Each
30th Jun 2010 10:10
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN) said Wednesday it purchased for cancellation 700,000 ordinary shares at a price of 2955 pence per share. -Shares at 0909 GMT up 278.5 pence, or 9.4%, at 3226.0 pence. -By Iain Packham, Dow Jones Newswires; 44-20-7842-9269; [email protected]
Read moreLondon open: Steady opening for blue chips
30th Jun 2010 08:56
London has stabilised after the pounding for share prices on both sides of the Atlantic. Anglo-Swedish drugs giant AstraZeneca is the best performer after it received a favourable US ruling in its battle to keep control of the patents to its best-selling cholesterol-lowering drug Crestor. BP is a
Read more